|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2400 N Street, NW |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20037 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1945-12
|
||||||||
|
6. House ID# 305320000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Nick Morse |
Date | 4/20/2017 3:04:54 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health care quality; physician and hospital quality; Patient Protection and Affordable Care Act/health care reform implementation; health care reform, including HR 1628, the American Health Care Act; medical liability reform, including HR 1215, the Protecting Access to Care Act; Physician Sunshine/Open Payments; informed consent and FDA-related research; unique device identifier policy and post-market surveillance for medical devices; Medical Device User Fee Act reauthorization; clinical data registries; the Common Rule and registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, HRSA, FDA, medical research, and prevention; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; S 477/HR 1222, the Congenital Heart Futures Reauthorization Act of 2017; HR 309, the National Diabetes Clinical Care Commission Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Natl Institutes of Health (NIH), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Kelly |
|
|
|
Nick |
Morse |
|
|
|
Lucas |
Sanders |
|
|
|
Lisa |
Goldstein |
|
|
|
Christina |
Hartman |
|
|
|
Christine |
Perez |
|
|
|
Natalie |
Torentinos |
|
|
|
Ann |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare physician payment; new/alternative payment models; Medicare coverage; Medicare hospital payment; Ways & Means Committee hospital payment project; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization; the Stark Law and the in-office ancillary services exception; Promoting Integrity in Medicare Act, HR 2066; Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; HR 1155, a bill to amend title XVIII of the Social Security Act to allow physician assistants, nurse practitioners, and clinical nurse specialists to supervise cardiac, intensive cardiac, and pulmonary rehabilitation programs; S 46, the Strengthening Medicare Intensive Cardiac Rehabilitation Programs Act of 2017; S 428, The Advancing Care for Exceptional Kids Act of 2017, a bill to allow a state, at its option, to elect to provide medical assistance for items and services furnished to eligible children with medically complex conditions enrolled in a Medicaid Children's Care Coordination (MCCC) program; Senate Finance Committee chronic care project; graduate medical education policy; end of life care; Children's Health Insurance Program (CHIP) extension; Puerto Rico Oversight, Management, and Economic Stability Act (PROMESA) implementation; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; repeal of the Independent Payment Advisory Board (IPAB), including S 251, the Protecting Medicare from Executive Action Act, S 260, the Protecting Seniors' Access to Medicare Act, SJ Res 16, SJ Res 17, and HR Res 51, joint resolutions approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Payment Advisory Board, and HR 849, a bill to repeal the IPAB; physician-owned hospital policy, including HR 1156; Medicaid eligibility: HR 829, Prioritizing the Most Vulnerable Over Lottery Winners Act of 2017, HR 181, Close Annuity Loopholes in Medicaid Act, and HR 705, Verify Eligibility Coverage Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Kelly |
|
|
|
Nick |
Morse |
|
|
|
Lucas |
Sanders |
|
|
|
Lisa |
Goldstein |
|
|
|
James |
Vavricek |
|
|
|
Christine |
Perez |
|
|
|
Debra |
Mariani |
|
|
|
Natalie |
Torentinos |
|
|
|
Ann |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Tobacco use prevention and smoking cessation; FDA regulation of tobacco; HR 1136, FDA Deeming Authority Clarification Act of 2017 and S 294/HR 564, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Kelly |
|
|
|
Nick |
Morse |
|
|
|
Lucas |
Sanders |
|
|
|
Lisa |
Goldstein |
|
|
|
Natalie |
Torentinos |
|
|
|
Christina |
Hartman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Menu labeling, nutrition, and dietary guidelines.
17. House(s) of Congress and Federal agencies Check if None
Agriculture - Dept of (USDA), Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Kelly |
|
|
|
Christina |
Hartman |
|
|
|
Lisa |
Goldstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |